Pembrolizumab + Lenvatinib
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Carcinosarcoma
Conditions
Uterine Carcinosarcoma, Advanced Uterine Carcinosarcoma
Trial Timeline
Dec 23, 2021 → Dec 23, 2026
NCT ID
NCT05147558About Pembrolizumab + Lenvatinib
Pembrolizumab + Lenvatinib is a phase 2 stage product being developed by Merck for Uterine Carcinosarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT05147558. Target conditions include Uterine Carcinosarcoma, Advanced Uterine Carcinosarcoma.
What happened to similar drugs?
4 of 18 similar drugs in Uterine Carcinosarcoma were approved
Approved (4) Terminated (7) Active (8)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07011849 | Phase 2 | Withdrawn |
| NCT06266338 | Phase 2 | Recruiting |
| NCT05545969 | Phase 2 | Withdrawn |
| NCT04865887 | Phase 2 | Recruiting |
| NCT05273554 | Phase 1 | Active |
| NCT04955743 | Phase 2 | Terminated |
| NCT05147558 | Phase 2 | Active |
| NCT05078931 | Phase 2 | Active |
| NCT04848337 | Phase 2 | Active |
| NCT04729348 | Phase 2 | Terminated |
| NCT04287829 | Phase 2 | Active |
| NCT04207086 | Phase 2 | Active |
| NCT03290079 | Phase 2 | Completed |
Competing Products
20 competing products in Uterine Carcinosarcoma